In vitro activity of amixicile against T. vaginalis from clinical isolates.
In vitro activity of amixicile against T. vaginalis from clinical isolates.
复制标题
amixicile 对临床分离株阴道毛滴虫的体外活性。
DOI：
10.1007/s00436-022-07567-8
复制
发表时间：
2022
影响因子：
2
通讯作者：
Warren,CirleA
中科院分区：
文献类型：
--
作者：
Jain,Eisha;Zaenker,EdnaI;Hoffman,PaulS;Warren,CirleA
滴虫病是一种由原生动物阴道毛滴虫引起的性传播感染，阴道毛滴虫是全球女性阴道炎和男性尿道炎的主要病原体。甲硝唑是滴虫病的标准治疗药物，替硝唑是二线药物。目前还没有FDA批准的非硝基咪唑替代疗法来治疗耐药菌株。本研究通过体外药敏试验比较了新合成的非硝基咪唑类口服药物阿米西林与甲硝唑及阿米西林的合成前体硝唑尼特的疗效。一株来自ATCC的标准株和三株患者分离的OFT株。在厌氧条件下，用阴道化来比较处理。甲硝唑、硝唑尼特和阿米西林的最小抑菌浓度分别为12.5gμM、100gμM和6.25gμM。这些结果表明，阿米西林可能具有很强的抗病活性。作为甲硝唑治疗滴虫病的潜在替代品，阴道感染和阴道感染值得进一步研究。
Trichomoniasis is a sexually transmitted infection in humans caused by the protozoanTrichomonas vaginalis,the leading causative agent of vaginitis in women and urethritis in men worldwide. Metronidazole is the standard treatment for trichomoniasis, with tinidazole as the second line. There are currently no FDA-approved non-nitroimidazole alternative treatments for resistant strains. This study compares the efficacy of a newly synthesized non-nitroimidazole oral drug, amixicile, to that of both metronidazole and the synthetic precursor of amixicile, nitazoxanide with in vitro sensitivity testing. One standard strain from ATCC and three patient-isolated strains ofT. vaginaliswere used to compare treatments under anaerobic conditions. The minimum inhibitory concentration for metronidazole, nitazoxanide, and amixicile were 12.5 μM, 100 μM, and 6.25 μM, respectively. These results suggest that amixicile may be highly active againstT. vaginalisand warrants further investigation as a potential alternative to metronidazole in the treatment of trichomoniasis.